Skip to content
Search AI Powered

Latest Stories

NICE's draft guidance against use of Vertex therapies may upset new cystic fibrosis patients

Patients who are already using the Vertex therapies can continue to use them, the guideline is open for consultation until 24 November

Modulator therapies, manufactured by Vertex Pharmaceuticals (VRTX.O), may no longer be available for new cystic fibrosis (CF) patients in the UK.


A draft guidance recently published by the National Institute for Health and Care Excellence (NICE) stated that it would not recommend the use of Kaftrio, Symkevi and Orkambi on new CF patients.

Kaftrio and Symkevi are currently recommended for the treatment of cystic fibrosis in patients aged 6 years and older, while Orkambi is used for patients aged 1 and older.

The NICE draft guidance highlighted medicine costs and the strain on resources and finances faced by the National Health Service (NHS) as reasons for removing these drugs.

The guidance stated: "Even when considering the condition’s severity, and its effect on quality and length of life, the most likely cost-effectiveness estimates for IVA–TEZ–ELX, LUM–IVA and TEZ–IVA are above the range that NICE considers an acceptable use of NHS resources. So, they are not recommended."

The list price of a 56-tablet pack of Kaftrio is £8,346.30, £6,293.91 for a 28-tablet pack of Symkevi and £8,000 for a 112-tablet pack of Orkambi (excluding VAT).

However, the NICE's draft guidance will not affect patients who are already using the Vertex therapies.

The proposals, if enacted, would restrict the use of these therapies on new patients under National Health Service (NHS) care. The guideline is open for consultation until 24 November.

Cystic Fibrosis is a common inherited condition that affects around 100,000 people worldwide. In the UK, it is estimated to affect about one in every 2,500 newborn babies.

The lungs of those with the condition become filled with thick sticky mucus, which makes them vulnerable to recurrent chest infections, and breathing and digestion problems.

Over the years, the affected lungs become damaged and may eventually stop working.

The Vertex drugs “treat the underlying cause of cystic fibrosis” rather than just addressing symptoms of the disease. The drugs, when approved, were hailed as game-changing, life-extending advances.

In 2019, the NHS signed a deal with Vertex and included these drugs in its prescription list.

The deal allowed the pharmaceutical company to collect clinical data in the real world, ahead of a formal appraisal by NICE.

Vertex has expressed disappointment with the draft NICE appraisal guidance issued about their drugs.

Reuters cited a statement from the company that read: "We believe that the committee has not fully considered all of (the) real-world evidence and we will be providing additional information and analysis to be taken into account.”

Further, the company stated that the long-term costs of caring for cystic fibrosis patients are being underestimated by NICE.

However, John Stewart, national director for specialised commissioning at NHS England, told the publication said the health service would continue to work with Vertex and NICE to make the medicines available “in a way that is fair to patients, and fair to taxpayers.”

More For You

New professional liability insurance policy for RPS members launched

The insurance will be provided to members at cost, with no profit made by RPS.

gettyimages

RPS launches professional liability insurance for members

The Royal Pharmaceutical Society (RPS) has launched a new professional liability insurance policy, designed to empower pharmacists to work confidently and deliver high-quality care, knowing they are protected.

Exclusively available to its members, the comprehensive and affordable insurance has been developed in collaboration with global professional services firm Aon.

Keep ReadingShow less
Scottish community pharmacist working in high street pharmacy with supportive environment

The PDA wants investment to reach those who deliver services to patients every day

Pic credit: iStock

Funding boost in Scotland “needs to work for not just pharmacy owners but pharmacists too”, says PDA

An increase in funding for community pharmacies in Scotland needs to lead to a greater focus on supporting pharmacists rather than “simply sustain business models”, according to the Pharmacy Defence Association (PDA).

Earlier this week, Community Pharmacy Scotland (CPS) accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

Keep ReadingShow less
GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less